board-banner

GENETIC TECHNOLOGIES BOARD MEMBERS

The board of directors at Genetic Technologies shares over 100 years of managerial and financial experience and a formidable knowledge of the biotech and life sciences sectors.

Dr. Malcolm R. Brandon, B. Agr. Sci. PhD
Chairman

Dr. Brandon was appointed to the Board on 5 October 2009 and also serves on the Company’s Audit Committee. He has over 36 years experience in commercially focused research and development and in building successful companies which have commercialised a wide range of Australian and international technologies. Mr. Brandon is currently Managing Director of genetics and artificial animal breeding company Clone International which uses cloning technologies to preserve the genetics of elite animals.

Mr. Grahame Leonard, AM, BA (Hons), LLB, CA, CPA, FAICD (Dip), AFAIM, OA
Non – Executive Director

Mr Leonard was appointed to the Board on 29 November 2013 and also serves as Chairman of the Company’s Audit Committee. He is a qualified Lawyer and Chartered Accountant. He brings over 35 years’ experience in the corporate world including Lysaght (BHP), BTR Nylex and The Thompson Corporation. His numerous community positions include former Commissioner, Victorian Multicultural Commission, former Chair, Victorian Government Multifaith Advisory Group and former Director of Transparency International Australia, (the Australian arm of the international anti-corruption watchdog).

Dr. Paul Kasian, PhD, MBA, GAICD
Non – Executive Director

Dr. Kasian was appointed to the Board on 12 December 2013. He brings to the Board a combination of expertise in strategic business leadership and biotech investment giving him a deep understanding on key value drivers for companies in generating shareholder value. He is an experienced executive director with demonstrated domestic and international success in funds management, encompassing senior leadership, investment and risk roles.

Dr Kasian has held senior leadership positions in a number of investment groups, and has significant funds management experience in Australia leading investment in the healthcare and life sciences sector. He holds a PhD in Microbiology and a Master of Business Administration, both from the University of Melbourne, and is a Graduate Member of the Australian Institute of Company Directors. Dr Kasian is also a Non-Executive Director of IODM Limited (ASX: IOD), ELK OrthoBiologics and Blockchain Global Limited

Dr. Lindsay Wakefield, MBBS
Non – Executive Director

Dr. Wakefield was appointed to the Board on September 24 2014. He started Safetech in 1985 and over the next 25 years Safetech became a force in the Australian material handling and lifting equipment market, designing and manufacturing a wide range of industrial products. In 1993, he left Medicine to become the fulltime CEO of the Company. In 2006 Safetech was awarded the Telstra Australian National Business of the Year.In 2013 Safetech merged to become STS Safetech Tieman Solutions and Dr. Wakefield has continued as the CEO of the Company. It is Australia’s largest manufacturer and supplier of dock equipment, freight hoists and custom lifting solutions. STS employs approximately 100 people.Dr. Wakefield has been a keen Biotech investor for the past 20 years, often at a mezzanine level.

Eutillio Buccilli, CPA
Executive Director

Mr Buccilli was appointed to the Board on June 12, 2015. He joined the Company in June 2014 as Chief Financial Officer. In November 2014 he was appointed Chief Operating Officer and subsequently appointed Chief Executive Officer in February 2015.

Mr Buccilli has more than 35 years senior management experience in the financial services, contracting and recruitment, property and retail industries in Australia and the U.S. He has held senior management positions with blue chip corporations such as General Electric, Computer Science Corporation, Coles Myer and Challenger Limited. Whilst at GE, Mr Buccilli was seconded to the U.S., where he worked at the GE Capital Headquarters located in Stamford Connecticut.

As a Director, Eutillio will be able to augment his significant contribution to the growth and strategic direction of the Company through his extensive financial, corporate governance, commercial experience and fund raising experience.